Stockscreener 앱 받기
3.59
0.00%
0.00
전일 마감가:
$3.59
열려 있는:
$3.62
하루 거래량:
91,853
Relative Volume:
0.62
시가총액:
$169.44M
수익:
$7.15M
순이익/손실:
$-20.60M
주가수익비율:
7.5643
EPS:
0.4746
순현금흐름:
$-97.99M
1주 성능:
-5.77%
1개월 성능:
+8.79%
6개월 성능:
+89.95%
1년 성능:
+84.10%
1일 변동 폭
$3.55
$3.73
1주일 범위
$3.40
$3.93
52주 변동 폭
$1.39
$4.4799
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
명칭
Whitehawk Therapeutics Inc
전화
551-321-2234
주소
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
3.59 | 169.44M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-05 | 개시 | Oppenheimer | Outperform |
| 2024-08-27 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 개시 | Jefferies | Buy |
| 2021-10-01 | 개시 | Cowen | Outperform |
| 2021-09-14 | 개시 | Ladenburg Thalmann | Buy |
| 2021-09-08 | 개시 | Piper Sandler | Overweight |
모두보기
Whitehawk Therapeutics Inc 주식(WHWK)의 최신 뉴스
Smart Money: Will Whitehawk Therapeutics Inc outperform the market in YEARMarket Movement Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Nasdaq Moves: Can Whitehawk Therapeutics Inc reach resistance levels soon2026 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn
Aug Selloffs: Can Whitehawk Therapeutics Inc reach resistance levels soon2026 Intraday Action & Technical Buy Zone Confirmation - baoquankhu1.vn
Bank Watch: What are Whitehawk Therapeutics Incs earnings expectationsVolume Spike & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Meme Stocks: Will Whitehawk Therapeutics Inc benefit from government policyWeekly Trading Summary & Intraday High Probability Setup Alerts - baoquankhu1.vn
Wall Street Zen Upgrades Whitehawk Therapeutics (NASDAQ:WHWK) to Hold - MarketBeat
Whitehawk Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 3350 | US00032Q1040 - marketscreener.com
Aug Technicals: Can Whitehawk Therapeutics Inc sustain its profitability2026 Biggest Moves & Entry Point Confirmation Signals - baoquankhu1.vn
Pullback Watch: Does Whitehawk Therapeutics Inc have a sustainable dividendWeekly Stock Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - ChartMill
Whitehawk Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aug Patterns: How does Whitehawk Therapeutics Inc score in quality rankingsMarket Sentiment Report & Real-Time Market Trend Scan - baoquankhu1.vn
Inside Whitehawk's 3 next-gen cancer drug conjugates debuting at AACR 2026 - Stock Titan
Whitehawk Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsWHWK - GuruFocus
Oppenheimer Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK) - The Globe and Mail
Suvretta Capital Management LLC Buys Shares of 3,700,000 Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC - MarketBeat
Whitehawk Therapeutics (WHWK) Swings To US$0.37 EPS Profit Challenging Bearish Turnaround Skepticism - simplywall.st
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK) - The Globe and Mail
Whitehawk Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Whitehawk Therapeutics 2025 10-K Overview: Next-Generation ADC Cancer Therapies, Pipeline, and Strategic Partnerships - Minichart
WHITEHAWK THERAPEUTICS ($WHWK) Releases Q4 2025 Earnings - Quiver Quantitative
Whitehawk Therapeutics Q4 EPS $(0.34) Misses $(0.13) EstimateWhitehawk Therapeutics (NASDAQ:WHWK) - Benzinga
Whitehawk Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs - TradingView
Whitehawk Therapeutics (WHWK) boosts 2025 cash to $145.7M and advances ADC pipeline - Stock Titan
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire
Whitehawk Therapeutics (WHWK) price target increased by 11.11% to 5.10 - MSN
David James Lennon Sells 5,100 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock - MarketBeat
Whitehawk Therapeutics (WHWK) CEO sells shares to cover RSU tax - Stock Titan
Whitehawk Therapeutics (WHWK) CFO sells shares to cover tax bill - Stock Titan
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027 - MarketBeat
Jones Trading initiates coverage of Whitehawk Therapeutics (WHWK) with buy recommendation - MSN
Why Whitehawk Therapeutics Inc. stock is a value investor pickEarnings Beat & Verified Chart Pattern Trade Signals - Naître et grandir
Insider Trends: What are the risks of holding Whitehawk Therapeutics IncWeekly Risk Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Can Whitehawk Therapeutics Inc reach resistance levels soon2025 Market Trends & Low Risk Entry Point Guides - baoquankhu1.vn
Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027 - Defense World
Aug Closing: Can Whitehawk Therapeutics Inc reach resistance levels soonJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Whitehawk Therapeutics : Corporate Presentation March 2026 - marketscreener.com
WHWK: Three differentiated ADCs in parallel, targeting broad cancers with best-in-class stability and safety - TradingView
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
Cancer drug developer Whitehawk lines up three March investor talks - Stock Titan
Whitehawk Therapeutics (WHWK) Price Target Increased by 11.11% to 5.10 - Nasdaq
Aadi Bioscience Conference: CEO Spotlights Whitehawk ADC Pipeline, Cash Runway Through 2028 - Yahoo Finance
WHWK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
WHWKWhitehawk Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Cancer drug developer Whitehawk joins Oppenheimer health conference - Stock Titan
Can Whitehawk Therapeutics Inc. (3350) stock sustain double digit ROEJuly 2025 Chart Watch & Low Risk Entry Point Guides - mfd.ru
Can Whitehawk Therapeutics Inc. (3350) stock reach $200 price targetMarket Sentiment Report & Daily Entry Point Trade Alerts - mfd.ru
How Whitehawk Therapeutics Inc. stock reacts to global recession fearsTrade Entry Summary & Fast Momentum Entry Tips - mfd.ru
Will Whitehawk Therapeutics Inc. outperform tech stocksJuly 2025 Volume & High Win Rate Trade Tips - mfd.ru
Is Whitehawk Therapeutics Inc.’s growth already priced in2025 Fundamental Recap & High Accuracy Investment Entry Signals - mfd.ru
Whitehawk Therapeutics Inc (WHWK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):